Novo Nordisk Tanks 30%, P&G Takes a Tariff Hit & SoFi’s Monster Second Quarter
Prof G Markets
00:00
Novo Nordisk's Struggles Amidst Eli Lilly's Success
This chapter explores Novo Nordisk's recent challenges in the competitive pharmaceutical landscape, particularly against Eli Lilly. It underscores the importance of acknowledging market difficulties and the impact of silence on investor confidence, as reflected in the company's declining stock price.
Transcript
Play full episode
